Link between different forms of menopausal hormone therapy and breast cancer incidence

https://www.eurekalert.org/pub_releases/2019-08/tl-pss082719.php

News Release 29-Aug-2019
The Lancet: New analyses of the worldwide epidemiological evidence demonstrate link between different forms of menopausal hormone therapy and breast cancer incidence, and find that some risk persists for many years
The Lancet


For women of average weight in Western countries, five years of menopausal hormone therapy (MHT), starting at age 50 years, would increase breast cancer incidence from age 50 to 69 years by about one additional case in every 50 users of oestrogen plus daily progestogen MHT, one in every 70 users of oestrogen plus intermittent progestogen MHT, and one in every 200 users of oestrogen-only MHT.

After ceasing MHT, some excess risk persists for more than 10 years - the size of this risk depended on the duration of previous use. If a woman had used MHT for less than a year, however, there was little excess risk thereafter.

•••••